Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.73 |
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.73 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.52 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420150 | 0.99 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL30050709 | 0.99 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| Phosphoric Acid SCHEMBL9905234 | 0.98 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL444904 | 0.91 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL9905233 | 0.91 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL419889 | 0.88 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12486604 | 0.86 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL3698210 | 0.86 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL3709602 | 0.85 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL15042947 | 0.85 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | claimed |
| US-20150099721-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-04-09 | — | — | US | claimed |
| EP-2849751-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2015-03-25 | — | — | EP | claimed |
| US-20140194388-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-10 | — | — | US | claimed |
| US-8742133-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | claimed |
| EP-2678014-A2 | PROSTATE CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2014-01-01 | — | — | EP | claimed |
| EP-2663305-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH PROTEASOME INHIBITORS | Synta Pharmaceuticals Corp. (US) | 2013-11-20 | — | — | EP | claimed |
| WO-2013170159-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-14 | — | — | WO | claimed |
| EP-2648708-A2 | COMBINATION FOR BREAST CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2013-10-16 | — | — | EP | claimed |
| EP-2616063-A1 | HSP90 INHIBITORS FOR TREATING NON-SMALL CELL LUNG CANCERS IN WILD-TYPE EGFR AND/OR KRAS PATIENTS | Synta Pharmaceuticals Corp. (US) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037072-A1 | HSP90 INHIBITORS FOR TREATING NON-SMALL CELL LUNG CANCERS IN WILD-TYPE EGFR AND/OR KRAS PATIENTS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-03-22 | — | — | WO | claimed |
| US-20120064175-A1 | HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients | SYNTA PHARMACEUTICALS CORP. | 2012-03-15 | — | — | US | claimed |
| WO-2011149824-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | WO | claimed |
| WO-2011146803-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-24 | — | — | WO | claimed |
| WO-2011133521-A2 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A VEGF INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-27 | — | — | WO | claimed |
| WO-2011133520-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-27 | — | — | WO | claimed |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-08-11 | — | — | US | claimed |
| WO-2011049946-A1 | COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-04-28 | — | — | WO | claimed |
| EP-2193135-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corp. (US) | 2010-06-09 | — | — | EP | claimed |
| WO-2009023211-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099721-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | ROS1, RET, HSP90AB1 | HSP90AA1 4/4885HSP90AB1 3/4885HSP90B1 7/4885 |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 2/4885 |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 3/4885 |
| US-20140194388-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 3/4885 |
| US-20120064175-A1 | HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.